China approves clinical trials for CanSino's inhaled Covid-19 vaccine


BEIJING (Xinhua): China's drug authority has approved clinical tests for an inhaled Covid-19 vaccine co-developed by domestic company CanSino Biologics, the Agence France-Presse (AFP) reported on Tuesday (March 23).

The clinical trial application of the vaccine, jointly developed by CanSino and the Beijing Institute of Biotechnology, was approved by the National Medical Products Administration (NMPA) on Monday, the pharmaceutical firm said in a filing on the Hong Kong stock exchange on Tuesday.

The safety and efficacy of the inhaled vaccine remain "subject to confirmation," the firm said.

The NMPA conditionally approved a recombinant vaccine for Covid-19 made by CanSino last month, which marked the first approved adenoviral vector vaccine for Covid-19.

More than 85.85 million doses of Covid-19 vaccines have been administered across China as of Wednesday, the National Health Commission said Thursday.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights

China , CanSino , vaccine , inhale , trials

   

Next In Aseanplus News

Asia's shining stars - China's Hou, India's Chanu and Indonesia's Aisah bag top three spots in weightlifting at Tokyo 2020
Philippines suspends social media Lyka’s payment system
Olympics-Gymnastics-Reign of Japan's 'King Kohei' Uchimura comes to an end
US trade agency drops tariff threat against Vietnam over currency practices
Batch of 736,000 Chinese vaccines arrives in Myanmar
With 50,000 cases a day, one country opens up as another suffers
PropertyGuru to go public in US$1.8 Billion SPAC deal
Phnom Penh lockdown extended to Aug 6; 32 more Covid-19 deaths, 860 infections in Cambodia
Macau scams: Almost RM328mil lost in over 5,000 cases since 2019, says Bukit Aman
Laos-China railway makes debut show for first completed station

Stories You'll Enjoy


Vouchers